

PRESS RELEASE

EBIDTA Doubles, Revenue Growth of 13% for Indoco in Q2FY21

Mumbai, 6th November, 2020: During the second quarter of FY 2020-21, Indoco Remedies revenue grew by 12.9 % at ₹ 322.5 crores, as against ₹ 285.6 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.7 % at ₹ 60.2 crores, compared to 11.3 % at ₹ 32.1 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 7.8 % at ₹ 25.1 crores, as against ₹ 7.3 crores, same quarter last year.

In the first half of the year, revenue grew by 10.6 % at ₹ 589.3 crores, as against ₹ 532.8 crores for the same period last year. EBIDTA to net sales for the first half of FY21 is 18.5 % at ₹ 109.0 crores, compared to 10.3 % at ₹ 54.9 crores, same period last year. For the first half, the Profit After Tax to net sales is 7.2 % at ₹ 42.3 crores, as against ₹ 9.5 crores, same period last year.

Commenting on the 2nd quarter FY21 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “The Company registered a double digit growth of 12.9 % in total revenue mainly driven by an impressive growth of 64% in the International Business. We expect strong operative leverage to continue.”

For the quarter ended Sept’20, the financials are as under: (₹ in Crores)

Particulars	July’20 - Sept’20	July’19 - Sept’19	Gw %
Net Revenues	327.6	292.0	12.2
EBIDTA	60.2	32.1	87.2
Operating Profit	51.4	20.4	152.2
Profit After Tax	25.1	7.3	242.6
EPS (Face value ₹ 2/-)	2.72	0.80	

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com